Home

To learn more about practical considerations when using PrXELJANZ®/PrXELJANZ® XR: 
 

XELJANZ in RA and PsA
XELJANZ XR in RA

Download “A Practical Guide to XELJANZ
and XELJANZ XR”

A Practical Guide to XELJANZ

XELJANZ in UC

Download “A Practical Guide to XELJANZ for UC”

A Practical Guide to XELJANZ for UC

Rheumatoid Arthritis
XELJANZ/XELJANZ XR (tofacitinib) in combination with methotrexate (MTX) is indicated for reducing the signs and symptoms of rheumatoid arthritis (RA) in adult patients with moderately to severely active RA who have had an inadequate response to MTX. In cases of intolerance to MTX, physicians may consider the use of XELJANZ/XELJANZ XR as monotherapy.

Use of XELJANZ/XELJANZ XR in combination with biological disease-modifying anti-rheumatic drugs (bDMARDs) or potent immunosuppressants such as azathioprine and cyclosporine is not recommended.
 
Psoriatic Arthritis
XELJANZ (tofacitinib) in combination with methotrexate (MTX) or another conventional synthetic disease-modifying antirheumatic drug (DMARD), is indicated for reducing the signs and symptoms of psoriatic arthritis (PsA) in adult patients with active PsA when the response to previous DMARD therapy has been inadequate.
 
Use of XELJANZ in combination with biological disease-modifying anti-rheumatic drugs (bDMARDs) or potent immunosuppressants such as azathioprine and cyclosporine is not recommended.
 
Ulcerative Colitis
XELJANZ (tofacitinib) is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) with an inadequate response, loss of response or intolerance to either conventional UC therapy or a TNFa inhibitor.
 
Use of XELJANZ in combination with biological UC therapies or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended.
 
For more information :
Please consult the XELJANZ/XELJANZ XR Product Monograph at http://pfizer.ca/pm/en/XELJANZ.pdf  for important information relating to contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use, which have not been discussed in this piece. The Product Monograph is also available by calling 1-800-463-6001.